UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

Electroencephalographic Density Spectral Array monitoring in pediatric anesthesia: clinical background and practical applications

Minerva anestesiologica, 2023-04, Vol.89 (4), p.351

2023

Volltextzugriff (PDF)

Midlatency auditory evoked potentials during anesthesia in children: A narrative review

Pediatric anesthesia, 2021-10, Vol.31 (10), p.1031-1039

2021

Volltextzugriff (PDF)

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations

Acta neuropathologica, 2021-06, Vol.141 (6), p.945-957

2021

Volltextzugriff (PDF)

The predictive value of the Pleth Variability Index on fluid responsiveness in spontaneously breathing anaesthetized children—A prospective observational study

Pediatric anesthesia, 2020-10, Vol.30 (10), p.1124-1131

2020

Volltextzugriff (PDF)

Electroencephalographic density spectral array monitoring during propofol/sevoflurane coadministration in children, an exploratory observational study

Anaesthesia critical care & pain medicine, 2024-04, Vol.43 (2), p.101342-101342, Article 101342

2024

Volltextzugriff (PDF)

Defining EGFR amplification status for clinical trial inclusion

Neuro-oncology (Charlottesville, Va.), 2019-10, Vol.21 (10), p.1263-1272

2019

Volltextzugriff (PDF)

Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors

EBioMedicine, 2020-06, Vol.56, p.102796-102796, Article 102796

2020

Volltextzugriff (PDF)

TMIC-39. PERIVASCULAR CONTAINMENT OF T CELLS IN IDH-MUTANT ASTROCYTOMA ASSOCIATES WITH HIGH ABUNDANCE OF GEMISTOCYTIC TUMOR CELLS AND IMMUNE STIMULATORY MICROGLIA

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v286-v287

2023

Volltextzugriff (PDF)

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

The lancet oncology, 2021-06, Vol.22 (6), p.813-823

2021

Volltextzugriff (PDF)

3D‐Engineered Scaffolds to Study Microtubes and Localization of Epidermal Growth Factor Receptor in Patient‐Derived Glioma Cells

Small (Weinheim an der Bergstrasse, Germany), 2022-12, Vol.18 (49), p.e2204485-n/a

2022

Volltextzugriff (PDF)

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

The lancet oncology, 2018-09, Vol.19 (9), p.1170-1179

2018

Volltextzugriff (PDF)

3D‐Engineered Scaffolds to Study Microtubes and Localization of Epidermal Growth Factor Receptor in Patient‐Derived Glioma Cells (Small 49/2022)

Small (Weinheim an der Bergstrasse, Germany), 2022-12, Vol.18 (49), p.n/a

2022

Volltextzugriff (PDF)

CSIG-24. LINEAR GRADING COEFFICIENT REVEALS EMBRYONIC DEVELOPMENT GENE SIGNATURE AS TREATMENT-INDEPENDENT PROGNOSTIC FACTOR IN IDH-MUTANT ASTROCYTOMA

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v45-v45

2023

Volltextzugriff (PDF)

Abstract 2071: Protein aggregate formation predicts clinical responses to EGFR tyrosine kinase inhibitors

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2071-2071

2019

Volltextzugriff (PDF)

DRES-14. PROTEIN AGGREGATE FORMATION PREDICTS CLINICAL RESPONSES TO EGFR TKIs

Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi78-vi78

2018

Volltextzugriff (PDF)

The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis

Neuro-oncology (Charlottesville, Va.), 2022-03, Vol.24 (3), p.429-441

2022

Volltextzugriff (PDF)

Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Clinical cancer research, 2022-06, Vol.28 (11), p.2440-2448

2022

Volltextzugriff (PDF)

Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post-hoc analysis of the EORTC randomized phase 3 CATNON trial

Clinical cancer research, 2022-06, Vol.28 (12), p.2527-2535

2022

Volltextzugriff (PDF)

EPCO-17. METHYLATION ANALYSIS OF MATCHED PRIMARY AND RECURRENT IDHmt ASTROCYTOMA; AN UPDATE FROM THE GLIOMA LONGITUDINAL ANALYSIS NL (GLASS-NL) CONSORTIUM

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi5-vi5

2021

Volltextzugriff (PDF)

Abstract 4886: Patients with EGFR amplification but without EGFRvIII expression have improved benefit compared to those with EGFRvIII expression in samples of the INTELLANCE2/EORTC1410 randomized phase II trial

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4886-4886

2019

Volltextzugriff (PDF)

PATH-11. PROGNOSTIC SIGNIFICANCE OF EPIGENETIC SUBTYPES AND CpGs ASSOCIATED WITH PROGRESSION TO G-CIMP LOW IN THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii166-ii166

2020

Volltextzugriff (PDF)

ACTR-47. PATIENTS WITH EGFR AMPLIFICATION BUT WITHOUT EGFRvIII EXPRESSION HAVE IMPROVED BENEFIT COMPARED TO THOSE WITH EGFRvIII EXPRESSION IN SAMPLES OF THE INTELLANCE 2/EORTC 1410 RANDOMIZED PHASE II TRIAL

Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi22-vi22

2018

Volltextzugriff (PDF)

Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.2023-2023

2018

Volltextzugriff (PDF)

PATH-51. OUTCOME IN 1p/19q NON-CO-DELETED GLIOMA TREATED AT FIRST RECURRENCE WITH TEMOZOLOMIDE W/WO BEVACIZUMAB IS DEPENDENT ON IDH, MGMT AND CIMP STATUS, BUT NOT ON GRADE AT FIRST DIAGNOSIS. A REPORT FROM THE RANDOMIZED PHASE II EORTC TAVAREC TRIAL

Neuro-oncology (Charlottesville, Va.), 2017-11, Vol.19 (suppl_6), p.vi182-vi182

2017

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(39)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Life Sciences & Biomedicine
(16)
Humans
(10)
Oncology
(8)
Clinical Neurology
(5)
Life Sciences
(5)
Neurosciences & Neurology
(5)
Abstracts
(4)
Anesthesiology
(4)
Brain Cancer
(4)
General & Internal Medicine
(4)
Glioma
(4)
Mutation
(4)
Patients
(4)
Anesthesia
(3)
Basic And Translational Investigations
(3)
Brain Neoplasms - Pathology
(3)
Chemotherapy
(3)
Child
(3)
Dna Methylation
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Electroencephalographic Density Spectral Array monitoring in pediatric anesthesia: clinical background and practical applications

Transcriptome analysis reveals tumor microenvironment changes in glioblastoma

Midlatency auditory evoked potentials during anesthesia in children: A narrative review

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations

The predictive value of the Pleth Variability Index on fluid responsiveness in spontaneously breathing anaesthetized children—A prospective observational study

Electroencephalographic density spectral array monitoring during propofol/sevoflurane coadministration in children, an exploratory observational study

Defining EGFR amplification status for clinical trial inclusion

Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors

TMIC-39. PERIVASCULAR CONTAINMENT OF T CELLS IN IDH-MUTANT ASTROCYTOMA ASSOCIATES WITH HIGH ABUNDANCE OF GEMISTOCYTIC TUMOR CELLS AND IMMUNE STIMULATORY MICROGLIA

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

3D‐Engineered Scaffolds to Study Microtubes and Localization of Epidermal Growth Factor Receptor in Patient‐Derived Glioma Cells

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

3D‐Engineered Scaffolds to Study Microtubes and Localization of Epidermal Growth Factor Receptor in Patient‐Derived Glioma Cells (Small 49/2022)

CSIG-24. LINEAR GRADING COEFFICIENT REVEALS EMBRYONIC DEVELOPMENT GENE SIGNATURE AS TREATMENT-INDEPENDENT PROGNOSTIC FACTOR IN IDH-MUTANT ASTROCYTOMA

Abstract 2071: Protein aggregate formation predicts clinical responses to EGFR tyrosine kinase inhibitors

DRES-14. PROTEIN AGGREGATE FORMATION PREDICTS CLINICAL RESPONSES TO EGFR TKIs

The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis

Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post-hoc analysis of the EORTC randomized phase 3 CATNON trial

EPCO-17. METHYLATION ANALYSIS OF MATCHED PRIMARY AND RECURRENT IDHmt ASTROCYTOMA; AN UPDATE FROM THE GLIOMA LONGITUDINAL ANALYSIS NL (GLASS-NL) CONSORTIUM

Abstract 4886: Patients with EGFR amplification but without EGFRvIII expression have improved benefit compared to those with EGFRvIII expression in samples of the INTELLANCE2/EORTC1410 randomized phase II trial

PATH-11. PROGNOSTIC SIGNIFICANCE OF EPIGENETIC SUBTYPES AND CpGs ASSOCIATED WITH PROGRESSION TO G-CIMP LOW IN THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON

ACTR-47. PATIENTS WITH EGFR AMPLIFICATION BUT WITHOUT EGFRvIII EXPRESSION HAVE IMPROVED BENEFIT COMPARED TO THOSE WITH EGFRvIII EXPRESSION IN SAMPLES OF THE INTELLANCE 2/EORTC 1410 RANDOMIZED PHASE II TRIAL

Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406)

PATH-51. OUTCOME IN 1p/19q NON-CO-DELETED GLIOMA TREATED AT FIRST RECURRENCE WITH TEMOZOLOMIDE W/WO BEVACIZUMAB IS DEPENDENT ON IDH, MGMT AND CIMP STATUS, BUT NOT ON GRADE AT FIRST DIAGNOSIS. A REPORT FROM THE RANDOMIZED PHASE II EORTC TAVAREC TRIAL

Suchergebnisse filtern